Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 (mut) measurable residual disease (MRD) using off‐label venetoclax in combination with low‐dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, includi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Haematol
Egile Nagusiak: Tiong, Ing S., Dillon, Richard, Ivey, Adam, Teh, Tse‐Chieh, Nguyen, Phillip, Cummings, Nicholas, Taussig, David C., Latif, Annie‐Louise, Potter, Nicola E., Runglall, Manohursingh, Russell, Nigel H., Raj, Kavita, Schwarer, Anthony P., Fong, Chun Yew, Grigg, Andrew P., Wei, Andrew H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Haematological Malignancy ‐ Clinical
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8048658/
https://ncbi.nlm.nih.gov/pubmed/32458446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16722
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak